Amneal Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
AMRX$21.28+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except per share amounts)
| Years Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Net revenue | $2,793,957 | $2,393,607 | $2,212,304 |
| Cost of goods sold | 1,773,519 | 1,573,042 | 1,427,596 |
| Gross profit | 1,020,438 | 820,565 | 784,708 |
| Selling, general and administrative | 476,436 | 429,675 | 399,700 |
| Research and development | 190,714 | 163,950 | 195,688 |
| In-process research and development impairment charges | — | 30,800 | 12,970 |
| Intellectual property legal development expenses | 5,845 | 3,828 | 4,358 |
| Acquisition, transaction-related and integration expenses | — | — | 709 |
| Restructuring and other charges | 2,355 | 1,749 | 1,421 |
| Change in fair value of contingent consideration | (930) | (14,497) | 731 |
| Insurance recoveries for property losses and associated expenses, net | — | — | (1,911) |
| Charges related to legal matters, net | 96,692 | 1,824 | 269,930 |
| Other operating income | — | (1,138) | (3,960) |
| Operating income (loss) | 249,326 | 204,374 | (94,928) |
| Other (expense) income: | |||
| Interest expense, net | (258,595) | (210,629) | (158,377) |
| Foreign exchange (loss) gain, net | (6,846) | 1,671 | (12,364) |
| Loss on refinancing | — | (40,805) | (291) |
| Increase in tax receivable agreement liability | (50,680) | (3,124) | (631) |
| Other income, net | 11,782 | 8,243 | 18,464 |
| Total other expense, net | (304,339) | (244,644) | (153,199) |
| Loss before income taxes | (55,013) | (40,270) | (248,127) |
| Provision for income taxes | 18,863 | 8,452 | 6,662 |
| Net loss | (73,876) | (48,722) | (254,789) |
| Less: Net (income) loss attributable to non-controlling interests | (43,010) | (35,271) | 125,241 |
| Net loss attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest | (116,886) | (83,993) | (129,548) |
| Accretion of redeemable non-controlling interest | — | — | (438) |
| Net loss attributable to Amneal Pharmaceuticals, Inc. | $(116,886) | $(83,993) | $(129,986) |
| Net loss per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders: | |||
| Basic and diluted | $(0.38) | $(0.48) | $(0.86) |
| Weighted-average common shares outstanding: | |||
| Basic and diluted | 308,978 | 176,136 | 150,944 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.